Characterization of in vitro glycation sites of tau

Parimala Nacharaju, Li Wen Ko, Shu Hui C Yen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Tau is a microtubule-associated protein that loses microtubule binding activity and aggregates into paired helical filaments (PHFs) in Alzheimer's disease. Nonenzymic glycation is one of the posttranslational modifications detected in PHF-tau, but not in normal tau. PHF-tau has reduced ability to bind to microtubules. To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4). The identified glycation sites are Lys-87, 132, 150, 163, 174, 225, 234, 259, 280, 281,347, 353, and 369. We have also studied glycation of another isoform of tau, which has only three microtubule binding domains (Tau-3). This isoform is modified by glucose 15-20% more slowly than Tau-4. However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3. Lys-150, 163, and 174 are located within or proximal to the sequence of tau that is involved in the microtubule nucleation activity, and Lys-259, 280, 281, 347, 353, and 369 are located in the microtubule binding domains. Glycation at these sites can affect the functional properties of tau, and advanced glycation at these sites might lead to the formation of insoluble aggregates similar to the ones seen in Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)1709-1719
Number of pages11
JournalJournal of Neurochemistry
Volume69
Issue number4
StatePublished - Oct 1997

Fingerprint

Microtubules
Protein Isoforms
Microtubule-Associated Proteins
Alzheimer Disease
Nucleation
Glucose
Aptitude
In Vitro Techniques
Post Translational Protein Processing

Keywords

  • Alzheimer's disease
  • Glycation sites
  • Tau glycation

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Characterization of in vitro glycation sites of tau. / Nacharaju, Parimala; Ko, Li Wen; Yen, Shu Hui C.

In: Journal of Neurochemistry, Vol. 69, No. 4, 10.1997, p. 1709-1719.

Research output: Contribution to journalArticle

Nacharaju, P, Ko, LW & Yen, SHC 1997, 'Characterization of in vitro glycation sites of tau', Journal of Neurochemistry, vol. 69, no. 4, pp. 1709-1719.
Nacharaju, Parimala ; Ko, Li Wen ; Yen, Shu Hui C. / Characterization of in vitro glycation sites of tau. In: Journal of Neurochemistry. 1997 ; Vol. 69, No. 4. pp. 1709-1719.
@article{bda0e7bd782f4b29a1664202653746b1,
title = "Characterization of in vitro glycation sites of tau",
abstract = "Tau is a microtubule-associated protein that loses microtubule binding activity and aggregates into paired helical filaments (PHFs) in Alzheimer's disease. Nonenzymic glycation is one of the posttranslational modifications detected in PHF-tau, but not in normal tau. PHF-tau has reduced ability to bind to microtubules. To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4). The identified glycation sites are Lys-87, 132, 150, 163, 174, 225, 234, 259, 280, 281,347, 353, and 369. We have also studied glycation of another isoform of tau, which has only three microtubule binding domains (Tau-3). This isoform is modified by glucose 15-20{\%} more slowly than Tau-4. However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3. Lys-150, 163, and 174 are located within or proximal to the sequence of tau that is involved in the microtubule nucleation activity, and Lys-259, 280, 281, 347, 353, and 369 are located in the microtubule binding domains. Glycation at these sites can affect the functional properties of tau, and advanced glycation at these sites might lead to the formation of insoluble aggregates similar to the ones seen in Alzheimer's disease.",
keywords = "Alzheimer's disease, Glycation sites, Tau glycation",
author = "Parimala Nacharaju and Ko, {Li Wen} and Yen, {Shu Hui C}",
year = "1997",
month = "10",
language = "English (US)",
volume = "69",
pages = "1709--1719",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Characterization of in vitro glycation sites of tau

AU - Nacharaju, Parimala

AU - Ko, Li Wen

AU - Yen, Shu Hui C

PY - 1997/10

Y1 - 1997/10

N2 - Tau is a microtubule-associated protein that loses microtubule binding activity and aggregates into paired helical filaments (PHFs) in Alzheimer's disease. Nonenzymic glycation is one of the posttranslational modifications detected in PHF-tau, but not in normal tau. PHF-tau has reduced ability to bind to microtubules. To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4). The identified glycation sites are Lys-87, 132, 150, 163, 174, 225, 234, 259, 280, 281,347, 353, and 369. We have also studied glycation of another isoform of tau, which has only three microtubule binding domains (Tau-3). This isoform is modified by glucose 15-20% more slowly than Tau-4. However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3. Lys-150, 163, and 174 are located within or proximal to the sequence of tau that is involved in the microtubule nucleation activity, and Lys-259, 280, 281, 347, 353, and 369 are located in the microtubule binding domains. Glycation at these sites can affect the functional properties of tau, and advanced glycation at these sites might lead to the formation of insoluble aggregates similar to the ones seen in Alzheimer's disease.

AB - Tau is a microtubule-associated protein that loses microtubule binding activity and aggregates into paired helical filaments (PHFs) in Alzheimer's disease. Nonenzymic glycation is one of the posttranslational modifications detected in PHF-tau, but not in normal tau. PHF-tau has reduced ability to bind to microtubules. To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4). The identified glycation sites are Lys-87, 132, 150, 163, 174, 225, 234, 259, 280, 281,347, 353, and 369. We have also studied glycation of another isoform of tau, which has only three microtubule binding domains (Tau-3). This isoform is modified by glucose 15-20% more slowly than Tau-4. However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3. Lys-150, 163, and 174 are located within or proximal to the sequence of tau that is involved in the microtubule nucleation activity, and Lys-259, 280, 281, 347, 353, and 369 are located in the microtubule binding domains. Glycation at these sites can affect the functional properties of tau, and advanced glycation at these sites might lead to the formation of insoluble aggregates similar to the ones seen in Alzheimer's disease.

KW - Alzheimer's disease

KW - Glycation sites

KW - Tau glycation

UR - http://www.scopus.com/inward/record.url?scp=0030964705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030964705&partnerID=8YFLogxK

M3 - Article

C2 - 9326300

AN - SCOPUS:0030964705

VL - 69

SP - 1709

EP - 1719

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -